

California, Berkeley (25). Secondary polyclonal antibodies used were Alexa Fluor 488 F(ab')<sub>2</sub> Fragment of Goat Anti-Mouse IgG (H+L) (Life Technologies) and Alexa Fluor 555 F(ab')<sub>2</sub> Fragment of Goat Anti-Rabbit IgG (H+L) (Life Technologies). PicoGreen staining of DNA and MitoTracker Red CM-H2XRos staining of mitochondria was performed according to the manufacturer's instructions (Life Technologies). Cells were stained with 2 µg/ml of Hoechst for 10 min and mounted in mounting medium (Dako, USA). Cell images were taken with a Leica TCS SP2 laser confocal scanning microscope (LCSM), and analyzed using Volocity (Version 6.2.1) and Imaris. Micrographs show cells representative of total cell populations. Scale bar represents 10 µm.

**Transfection** – A549 cells were transfected with siRNA of *POLR3G* (Qiagen, Netherlands) using Lipofectamine RNAiMAX Transfection Reagent (Life Technologies) according to manufacturer's instructions. AllStars Negative Control siRNA (Qiagen) was used as a control in transfection (siNEG), and its sequence was proprietary. The siPOLR3G sequences used were: siPOLR3G\_1, 5'-AAGGCACACCACTCACTAA TA-3', siPOLR3G\_2, 5'-TCAGAGTACTCAAGT GTACAA-3'.

**Immunoblotting** – Cells were lysed in cold RIPA buffer (Nacalai Tesque) and lysates were electrophoresed in 4-12% NuPAGE Bis-Tris gel (Life Technologies) before blotted onto PVDF membranes. Antibodies specific to DDX17 (sc-86409, Santa Cruz, USA), AGO2 (C34C6, Cell Signaling Technology, USA), and GAPDH (M171-3, MBL), and horseradish peroxidase-conjugated secondary antibodies (Cell Signaling Technology) were used to develop the blots, with Immobilon Western Chemiluminescent HRP Substrate (Milipore, Germany). Digital images were acquired using ImageQuant LAS 500 (GE Healthcare, United Kingdom).

**Immunoprecipitation and mass spectrometry** –  $2 \times 10^6$  A549 cells were seeded into 100-mm dishes and fixed in 1% paraformaldehyde (Nacalai Tesque) for 10 min, followed by treatment with 125 mM of Glycine (Wako, Japan) for 5 min. Cells were fractionated using MitoSciences cell fractionation kit (MS861, MitoSciences, USA). The cytosolic fraction was precleared by incubation with 5 µl of Protein G–Sepharose beads (GE Healthcare) at 4°C for 20 min on a rolling shaker. The cleared

supernatant was incubated at 4°C overnight on a rolling shaker with 10 µg/ml of RNA:DNA hybrid antibody and 10 µl of Protein G–Sepharose beads. Immunoprecipitates were washed subsequently with RIPA buffer, low salt buffer (20 mM Tris-HCL pH 8.1, 150 mM NaCl, 0.1% SDS, 1% Triton X-100, 2mM EDTA), high salt buffer (20 mM Tris-HCL pH 8.1, 600 mM NaCl, 0.1% SDS, 1% Triton X-100, 2mM EDTA), final wash (20 mM Tris-HCL pH 8.0, 0.1% SDS, 1% Triton X-100, 1 mM EDTA) and TE buffer. Beads were resuspended in TE buffer with 1% SDS and incubated at 65°C overnight to release protein complexes for subsequent gel electrophoresis. For mass spectrometry, similarly processed cell lysates were immunoprecipitated with RNA:DNA hybrid antibody, and silver stained using Silver Stain Plus Kit (Bio-Rad, USA) according to the manufacturer's instruction. Bands of interest were cut out and sent for mass spectrometry analysis at the Osaka University mass spectrometry facility.

**MiRNA microarray analysis** – A549 cells were treated with 10 µM of RNA POL III inhibitor for 24 hrs, or subsequently treated with 10 µM Ara-C or DMSO for 15 hrs. DMSO-treated cells served as a control. Total RNA was extracted by Trizol (Life Technologies) and labelled using a 3D-Gene miRNA labeling kit. The labelled RNA was hybridized to a human miRNA V19 microarray chip containing 2019 miRNA probes and analyzed on a ProScanArray™ microarray scanner (Toray Industries, Japan). MiRNA profiles were provided as sample-wise median-normalized data by Toray. Data were further normalized using all-sample quantile normalization protocol using the corresponding Bioconductor package developed by Bolstad et al. (26). Original miRNA profiles consisted of 2019 miRNA probes, of which only a small fraction showed significant expression in any of these experiments. After replacing the missing valued data (no expression observed) by the minimum of all observed expression values, miRNA probes that showed at least 3-fold differential expression between any pair of 4 experiments, were used for further quantitative analysis. Identified miRNA sequences were used to obtain predicted gene targets, as acquired from public domain resource, mir-DIANA (27). A P-value threshold of 0.05 and MicroT threshold of 0.8 was applied.

**MiRNA expression analysis** – After RNA extraction, cDNA was synthesized using miScript II RT kit (Qiagen). MiRNA levels were analysed using assay kits for mature miR-4499 (Qiagen), precursor (includes detection for precursor and primary miR) miR-4499 (Qiagen), TaqMan primary miR-4499 (Life Technologies), and quantified by qPCR using iTaq Universal SYBR Green Supermix (BioRad), or TaqMan Gene Expression Master Mix (Life Technologies). Precursor miR expression was determined as per the equation referenced in (28).

**Quantitative Real-time RT-PCR** – Performed as described in (9). The following primers were used: *XPO1*-5', 5'-AGGTTGGAGAAGTGATGC CA-3'; *XPO1*-3', 5'-GCACCAATCATGTACCC CAC-3'; *KPNB1*-5', 5'-GACCGACTACCCAGA CAGAG-3'; *KPNB1*-3', 5'-GACTCCTCCTAAG ACGACGG-3'; *NUP153*-5', 5'-GCCCAAATCTT CCTCTGCAG-3'; *NUP153*-3', 5'-GAAAGGAG CCACTGAAGCAC-3'; *HPRT1*-5', 5'-CCCTGG CGTCGTGATTAGTG-3'; *HPRT1*-3', 5'-TCGA GCAAGACGTTTCAGTCC-3'.

**Statistical analysis** – For statistical analysis, one-tailed Student's t-test ( $P < 0.05$ ) was used unless otherwise stated, after data were tested positive for normality by Shapiro-Wilk test. For data that failed normality test, non-parametric Mann-Whitney Wilcoxon Rank-Sum test was used. Error bars represent standard error unless otherwise stated in the figure legends. A P-value of  $* < 0.05$  was considered statistically significant.

## RESULTS

**Presence of RNA:DNA hybrids in the cytosol of human cells** – We previously reported the presence of cytosolic ssDNA and dsDNA in cancer cells using specific antibodies and the vital dye PicoGreen, which can detect dsDNA and RNA:DNA hybrids (9,29,30). Here, we sought to test if RNA:DNA hybrids are present in the cytosol of human cancer cell lines. PicoGreen stained DNA in the cytosol of the human lung carcinoma cell line A549 and other cancer cell lines (Fig. 1, *A* and *B*, and Fig. 2, *A* and *B*). Three-dimensional surface rendering of confocal images showed that the majority of extranuclear DNA is present outside of mitochondria (Fig. 1*B*). To analyze if RNA:DNA hybrids contribute to the PicoGreen signals in the cytosol, A549 cells were treated with RNase H,

which degrades RNA in RNA:DNA hybrids, prior to staining with PicoGreen (31). Pretreatment of cells with RNase H abrogated the cytosolic PicoGreen signals (Fig. 1, *A-C*). As expected, the staining of nuclear genomic DNA by PicoGreen was not changed.

To further investigate the presence of cytosolic RNA:DNA hybrids, we stained cells using the RNA:DNA hybrid-specific S9.6 antibody (25). In agreement with the PicoGreen, S9.6 staining of tumor cells A549, LoVo, HCT 116, HT29, HeLa, THP-1, and human fetal lung fibroblast (MRC-5) cells showed the presence of RNA:DNA hybrids in the cytosol and to a lesser extent in the nucleus (Fig. 1, *D* and *E*, and Fig. 2, *A* and *B*). As RNA:DNA hybrids can also form during replication of mitochondrial DNA (32), we co-stained cells with the mitochondria-specific vital dye MitoTracker. Three-dimensional surface rendering of confocal images showed that the majority of RNA:DNA hybrids were localized outside of mitochondria (Fig. 1*E*). Pre-treatment of cells with RNase H prior to S9.6 staining significantly reduced the cytosolic RNA:DNA hybrid staining (Fig. 1, *D-F*). S9.6 staining only partially co-stained with PicoGreen suggesting that PicoGreen stains cytosolic dsDNA and RNA:DNA hybrids in A549 cells (Fig. 1*G*). Consistent with this possibility, staining of A549 cells using a dsDNA-specific antibody showed the presence of cytosolic dsDNA, which partially colocalized with the cytosolic PicoGreen staining (Fig. 2*C*). In summary, our data show that RNA:DNA hybrids are constitutively present in the cytosol of all tested cells.

**Presence of cytosolic RNA:DNA hybrids depends on RNA Polymerase III** – RNA:DNA hybrids can occur during transcription of DNA (33). In addition, cytosolic DNA is transcribed by RNA polymerase III in the cytosol and potentially in the nucleus into a RNA:DNA hybrid and dsRNA intermediate (22,23). To understand the mechanism by which cytosolic RNA:DNA hybrids are generated and regulated, A549 cells were treated with POL III inhibitors prior to staining with S9.6 or PicoGreen (34). Treatment of A549 cells with the POL III inhibitor ML-60218 decreased the cytosolic RNA:DNA hybrid staining at doses above the published half-maximal inhibitory concentration ( $IC_{50}$ ), but had no effect on nuclear PicoGreen staining, but affected RNA:DNA hybrid staining at above  $IC_{50}$  (Fig. 3). Treatment of A549

cells with  $\alpha$ -amanitin, a POL II inhibitor, was toxic on cells as compared to POL III inhibitor ML-60218.

To investigate if genetic effect of POL III inhibition also reduced RNA:DNA hybrid levels, A549 cells were transfected with siRNA against POLR3G (siPOLR3G\_1 and siPOLR3G\_2), a subunit of the RNA POL III complex, or negative control siRNA (siNEG). Knockdown of POLR3G protein expression resulted in disappearance of cytosolic RNA:DNA hybrids by immunofluorescence staining, consistent with reduced POLR3G mRNA gene expression (Figure 4). In contrast, siNEG did not affect cytosolic RNA:DNA hybrid levels, nor POLR3G expression. This corroborated with previous results of POL III chemical inhibition, which decreased the presence of RNA:DNA hybrids.

In contrast to POL II, which is exclusively localized in the nucleus, a fraction of POL III is present in the cytosol. To investigate if cytosolic POL III contributes to the generation of RNA:DNA hybrids in the cytosol, we co-stained A549 cells for POLR3G, a subunit of the POL III complex, and RNA:DNA hybrids (35). No significant co-staining of POLR3G and S9.6 or PicoGreen was observed in the cytosol of A549 cells (Fig. 5A). Furthermore, POLR3G was largely localized in the nucleus suggesting that the presence of cytosolic RNA:DNA hybrids depends on nuclear POL III activity.

*Presence of cytosolic RNA:DNA hybrids is independent of DNA damage* – RNA:DNA hybrids can cause stalling of the replication fork and formation of dsDNA breaks (4,36,37). To test if stalling of replication forks and the associated DNA damage contributes to the presence of RNA:DNA hybrid in the cytosol, A549 cells were treated with cytarabine (Ara-C), a genotoxic DNA replication inhibitor used to treat leukemia, and aphidicolin, an inhibitor of DNA polymerases (38). Treatment with Ara-C or aphidicolin had no effect on the level of cytosolic RNA:DNA hybrids in A549 cells (Fig. 5, A and C). Moreover, Ara-C treatment did not increase the co-localization of POLR3G and RNA:DNA hybrids (Fig. 5, A and B).

To test if the cellular response to DNA damage is required for the presence of cytosolic RNA:DNA hybrids, we inhibited ATM and ATR, two kinases that initiate the DDR. We previously found that the presence of dsDNA in the cytosol of B-cell

lymphoma cells depends on the DDR (9). In contrast, inhibition of the DDR had no effect on the presence of RNA:DNA hybrids in the cytosol (Fig. 5D). Hence, unlike cytosolic dsDNA, RNA:DNA hybrid levels in the cytosol depend on POL III, but not DNA damage or the DDR.

*Cytosolic RNA:DNA hybrids bind members of the miRNA processing machinery* – To examine whether RNA:DNA hybrids interact with proteins in the cytosol, we performed immunoprecipitation experiments using the RNA:DNA-specific S9.6 antibody on cytosolic extracts of A549 cells. A fraction of the extracts was treated with RNase H before analysis to verify RNA:DNA hybrid-specific binding of proteins. Analysis by mass spectrometry identified DEAD (Asp-Glu-Ala-Asp) box polypeptide 5/17 (DDX5/DDX17), Argonaute (AGO 2), and Breast cancer 1 (BRCA-1) as proteins that immunoprecipitated in an S9.6-dependent manner (Fig. 6A). All three proteins are part of the miRNA processing machinery (39). Immunoblot analyses of immunoprecipitated proteins showed that DDX17 binding was consistent with the mass spectrometry analysis (Fig. 6B). AGO2 is a part of the miRNA-mediated DDR (40), and increases interaction with repair molecules during double-strand break (DSB) repair (41). Ara-C treatment increased interaction of S9.6 with AGO2 proteins (Fig. 6C). Consequently, components of the miRNA processing machinery are found to interact with cytosolic RNA:DNA hybrids, in the absence and increased interaction in the presence of DNA damage.

*RNA Polymerase III regulates the expression of specific miRNAs* – Next we sought to gain insights into the POL III-dependent mechanisms leading to the presence of cytosolic RNA:DNA hybrids. Our data support the possibility that POL III-mediated transcription of miRNAs is associated with the presence of cytosolic RNA:DNA hybrids. POL III is able to transcribe a subset of miRNAs in a cell-type-specific manner (42), or interact with canonical genes within a chromosome location that also encodes miRNAs (43). To determine if a subset of miRNAs are dependent on POL-III, we examined the POL III-dependent miRNA expression profile in A549 cells by comprehensive miRNA array analysis. To distinguish POL III effects from RNA:DNA hybrid-induced DNA damage, cells were treated with the genotoxic DNA replication inhibitor Ara-C or the POL III inhibitor

ML-60218. A total of 81 differentially expressed miRNAs were identified after comparison across the treatment groups (Fig. 7A). Strikingly, treatment of cells with POL III inhibitor resulted in significant down-regulation of only four miRNAs: miR-615-5p, miR-1178-5p, miR-4499, and miR-5571-3p (Fig. 7, A and B). The expression of miR-615-5p, miR-1178-5p, and miR-5571-3p was also decreased after Ara-C treatment, suggesting that the expression of these miRNAs is also downregulated by DNA damage. In contrast, miR-4499 is likely to be transcribed directly by POL III as Ara-C had no effect on its expression. Surprisingly, the expression of ten miRNAs was upregulated after treatment with the POL III inhibitor ML-60218, but not Ara-C (Fig. 7, A and B). To confirm if POL III directly regulated miR-4499 expression, miRNA expression of miR-4499 was measured after POL III treatment. Mature miR-4499 expression decreased after treatment, corresponding to miRNA microarray data (Fig. 7C). Precursor miR-4499 (pre-miR-4499) also decreased significantly while primary miR-4499 (pri-miR-4499) was not significantly affected (Fig. 7C). This suggested that POL III does not directly transcribe pri-miR-4499, but might regulate Drosha processing of pre-miR-4499 to affect mature miR-4499 expression.

In summary, our data indicate that POL III regulates the expression of a limited number of miRNAs, which may contribute to the presence of cytosolic RNA:DNA hybrids in A549 cells.

To investigate all the potential transcripts targeted by POL III-modulated miRNAs, a miRNA target prediction and pathway analysis was performed using the DIANA-miRPath software (<http://www.microrna.gr/miRPathv2>.) (27). Among the top ranked pathways, RNA transport and RNA surveillance pathways were identified to contain predicted genes that are targeted by two or more ML-60218-induced miRNAs (red boxes), while other transcripts are potentially targeted by a single miRNA (yellow boxes) (Fig. 8A). Hence, RNA transport or stability may contribute to the presence of RNA:DNA hybrids. To test the predictability of the DIANA-miRPath software, three genes *KPNB1*, *XPO1*, and *NUP153* were selected for mRNA expression detection after POL III inhibition. Gene expression of *XPO1* and *NUP153* were found to be downregulated by 1.6-fold and 3.3-fold respectively (Fig. 8B).

*Exportin 1 regulates transport of RNA:DNA hybrids from the nucleus to the cytosol* – Of the identified genes that were downregulated in response to RNA POL III inhibition, *XPO1* encodes for exportin 1, a protein involved in RNA transport and miRNA processing (44,45). To test if exportin 1 is involved in transport of nuclear RNA:DNA hybrids to the cytosol, cells were treated with Leptomycin B (LMB), an XPO1 inhibitor. Increasing concentrations of LMB decreased accumulation of cytosolic RNA:DNA hybrids, while cytosolic COX IV remained unchanged significantly (Fig. 9), suggesting that XPO1 function is required for the presence of RNA:DNA hybrids.

## DISCUSSION

Here we show the existence of endogenous RNA:DNA hybrids in the cytosol of a variety of human cells, including cancer cells. We previously found that ssDNA and dsDNA in the cytosol of B-cell lymphomas depended on DNA damage and the ensuing DDR (9). In contrast, treatment of cells with genotoxic agents or blocking of the DDR had no effect on the levels of cytosolic RNA:DNA hybrids suggesting the presence of RNA:DNA hybrids is regulated by different pathways. Consistent with this conclusion, inhibition of POL III lead to the disappearance of RNA:DNA hybrids in the cytosol. Interestingly, POL III inhibitors also abrogated cytosolic PicoGreen staining, which stains cytosolic dsDNA and in A549 cells, suggesting that POL III contributes to the presence of dsDNA in A549 cells. It is possible that POL III dependent R-loops, which contain RNA:DNA hybrids, contribute to the presence of cytosolic dsDNA in tumor cells by stalling replication forks, which results in DNA damage and the activation of the DDR (37). In agreement with this possibility, it was recently shown that the DDR is activated in cells that are deficient in the R-loop resolving enzyme *Rnaseh2* (46). Furthermore, overexpression of *Rnaseh1*, which degrades the RNA strand in RNA:DNA hybrids, decreased the levels of cytosolic ssDNA and dsDNA in tumor cells (Shen et al., submitted).

In previously published studies, virus or bacteria-derived cytosolic RNA:DNA hybrids were described in human cells (12,13). Our data show that RNA:DNA hybrids can also exist in the cytosol of non-infected cells. All the cells used in our study

were cultured under sterile conditions and were mycoplasma free. Cells were further treated with Plasmocin to exclude potential undetected mycoplasma contaminations suggesting that cytosolic RNA:DNA hybrids are not a result of infection of the tested cells. RNA:DNA hybrids were also reported to form in the mitochondrial genome of non-infected cells (47,48). Co-staining of cells with mitochondria-specific dyes or marker, showed that extramitochondrial RNA:DNA hybrids are present in human cells. Furthermore, inhibition of POL III, which has not been found to localize to mitochondria or extranuclear RNA:DNA hybrids, abrogated the presence of RNA:DNA hybrids. In addition, exportin-1 inhibition of nuclear export decreased cytosolic RNA:DNA hybrids, suggesting RNA:DNA hybrids are derived from the nucleus. In summary, our data suggest that nuclear POL III activity is required for the presence of RNA:DNA hybrids in the cytosol of non-infected cells.

Each polymerase in the RNA POL family of proteins has defined transcriptional roles (49). POL I transcribes ribosomal RNA, POL II transcribes protein-encoding mRNA, while POL III transcribes 5S rRNA, tRNA, and certain retroelements. Non-coding RNAs can be transcribed by all three polymerases in eukaryotic cells (50). Strikingly, the inhibition of POL III, but not DNA polymerases, abrogated the presence of cytosolic RNA:DNA hybrids suggesting that POL III transcripts are required for the existence of such structures in the cytosol. In contrast, the level of nuclear RNA:DNA hybrids was not decreased in response to POL III inhibition for PicoGreen stains, as well as at low inhibition for RNA:DNA hybrid antibody stains, consistent with previous reports that the majority of RNA:DNA hybrids in the nucleus are transcribed by POL II (51).

Immunoprecipitation experiments suggest that cytosolic RNA:DNA hybrids bind to the DDX17-containing DROSHA miRNA complex (52). It is therefore conceivable that cytosolic RNA:DNA hybrids consist of POL III-transcribed miRNAs. Analysis of the miRNA expression profile showed that POL III modulates the expression of a small number of miRNAs, most of which were upregulated upon POL III inhibition, suggesting a complex regulation of these miRNAs by POL III in A549 cells. Surprisingly, POL III inhibition reduced the expression of only four miRNAs. Three

out of the four miRNAs were also downregulated by Ara-C, which does not modulate the levels of cytosolic RNA:DNA hybrids. Hence, our data suggest that cytosolic RNA:DNA hybrids consist of very limited number of POL III-transcribed miRNAs, possibly only miR-4499. However miR expression of miR-4499 after POL III treatment suggested that POL III does not directly transcribe pri-miR-4499, and POL III may instead affect Dicer processing of precursor miR-4499. Alternatively, it is conceivable that POL III-modulated miRNAs target transcripts of genes, which regulate the presence of cytosolic RNA:DNA hybrids. Consistent with this possibility, many POL III modulated miRNAs potentially target RNA transport and mRNA stability pathways. Two out of three selected potential targets from the pathways were shown to be downregulated after POL III inhibition, consistent with previous results of miRNA overexpression that would suppress gene expression of target genes. Out of the affected target genes, exportin-1 inhibition was also shown to prevent accumulation of cytosolic RNA:DNA hybrids, suggesting that RNA POL III may have multiple functions in the generation of RNA:DNA hybrids, and also possibly regulating miRNAs that modulate the transport of nuclear RNA:DNA hybrids into the cytosol. Cytosolic RNA:DNA hybrids may also be generated by the transcription of cytosolic DNA by POL III, which was reported to detect cytosolic DNA and induce type I interferons through the RIG-I pathway (20-22). However, POL III did not co-localize with cytosolic DNA or cytosolic RNA:DNA hybrids. Furthermore, inhibition of POL III did not reduce type I interferon transcript levels (data not shown) consistent with the conclusion that neither POL III nor other type I interferon-inducing sensors recognize DNA in the cytosol of A549 cells. In agreement with this observation, no known cytosolic DNA or RNA sensor precipitated with RNA:DNA hybrids. Finally, it is conceivable that reverse transcription of POL III-transcribed retroelements produces RNA:DNA intermediates in the cytosol similar to replicating RNA viruses (6,53,54).

In summary, we show that POL III activity leads to the presence of RNA:DNA hybrids in human cells. The functional role of RNA:DNA hybrids remains to be further investigated, but RNA:DNA hybrids may modulate cellular functions or

contribute to immune recognition by activating TLR9 or the NLRP3 inflammasome in dendritic cells (12,13).

#### REFERENCES:

1. Aguilera, A., and Garcia-Muse, T. (2012) R loops: from transcription byproducts to threats to genome stability. *Mol Cell* **46**, 115-124
2. Komissarova, N., Becker, J., Solter, S., Kireeva, M., and Kashlev, M. (2002) Shortening of RNA:DNA hybrid in the elongation complex of RNA polymerase is a prerequisite for transcription termination. *Mol Cell* **10**, 1151-1162
3. Kireeva, M. L., Komissarova, N., Waugh, D. S., and Kashlev, M. (2000) The 8-nucleotide-long RNA:DNA hybrid is a primary stability determinant of the RNA polymerase II elongation complex. *J Biol Chem* **275**, 6530-6536
4. Aguilera, A., and Garcia-Muse, T. (2012) R loops: from transcription byproducts to threats to genome stability. *Mol Cell* **46**, 115-124
5. Maizels, N. (2006) Dynamic roles for G4 DNA in the biology of eukaryotic cells. *Nat Struct Mol Biol* **13**, 1055-1059
6. Wahba, L., Amon, J. D., Koshland, D., and Vuica-Ross, M. (2011) RNase H and multiple RNA biogenesis factors cooperate to prevent RNA:DNA hybrids from generating genome instability. *Mol Cell* **44**, 978-988
7. Biffi, G., Tannahill, D., McCafferty, J., and Balasubramanian, S. (2013) Quantitative visualization of DNA G-quadruplex structures in human cells. *Nat Chem* **5**, 182-186
8. Wahba, L., Gore, S. K., and Koshland, D. (2013) The homologous recombination machinery modulates the formation of RNA-DNA hybrids and associated chromosome instability. *Elife* **2**, e00505
9. Lam, A. R., Le Bert, N., Ho, S. S., Shen, Y. J., Tang, M. L., Xiong, G. M., Croxford, J. L., Koo, C. X., Ishii, K. J., Akira, S., Raulet, D. H., and Gasser, S. (2014) RAE1 Ligands for the NKG2D Receptor Are Regulated by STING-Dependent DNA Sensor Pathways in Lymphoma. *Cancer Res*
10. Theofilopoulos, A. N., Kono, D. H., Beutler, B., and Baccala, R. (2011) Intracellular nucleic acid sensors and autoimmunity. *J Interferon Cytokine Res* **31**, 867-886
11. Jounai, N., Kobiyama, K., Takeshita, F., and Ishii, K. J. (2012) Recognition of damage-associated molecular patterns related to nucleic acids during inflammation and vaccination. *Front Cell Infect Microbiol* **2**, 168
12. Kailasan Vanaja, S., Rathinam, V. A., Atianand, M. K., Kalantari, P., Skehan, B., Fitzgerald, K. A., and Leong, J. M. (2014) Bacterial RNA:DNA hybrids are activators of the NLRP3 inflammasome. *Proc Natl Acad Sci U S A*
13. Rigby, R. E., Webb, L. M., Mackenzie, K. J., Li, Y., Leitch, A., Reijns, M. A., Lundie, R. J., Revuelta, A., Davidson, D. J., Diebold, S., Modis, Y., Macdonald, A. S., and Jackson, A. P. (2014) RNA:DNA hybrids are a novel molecular pattern sensed by TLR9. *Embo J*
14. Dieci, G., Conti, A., Pagano, A., and Carnevali, D. (2013) Identification of RNA polymerase III-transcribed genes in eukaryotic genomes. *Biochim Biophys Acta* **1829**, 296-305
15. Dieci, G., Fiorino, G., Castelnuovo, M., Teichmann, M., and Pagano, A. (2007) The expanding RNA polymerase III transcriptome. *Trends Genet* **23**, 614-622
16. Lorenzen, K., Vannini, A., Cramer, P., and Heck, A. J. (2007) Structural biology of RNA polymerase III: mass spectrometry elucidates subcomplex architecture. *Structure* **15**, 1237-1245
17. Gjidoda, A., and Henry, R. W. (2013) RNA polymerase III repression by the retinoblastoma tumor suppressor protein. *Biochim Biophys Acta* **1829**, 385-392
18. Marshall, L., and White, R. J. (2008) Non-coding RNA production by RNA polymerase III is implicated in cancer. *Nat Rev Cancer* **8**, 911-914

19. Veras, I., Rosen, E. M., and Schramm, L. (2009) Inhibition of RNA polymerase III transcription by BRCA1. *J Mol Biol* **387**, 523-531
20. Schwartz, L. B., Sklar, V. E., Jaehning, J. A., Weinmann, R., and Roeder, R. G. (1974) Isolation and partial characterization of the multiple forms of deoxyribonucleic acid-dependent ribonucleic acid polymerase in the mouse myeloma, MOPC 315. *J Biol Chem* **249**, 5889-5897
21. Jaehning, J. A., and Roeder, R. G. (1977) Transcription of specific adenovirus genes in isolated nuclei by exogenous RNA polymerases. *J Biol Chem* **252**, 8753-8761
22. Chiu, Y. H., Macmillan, J. B., and Chen, Z. J. (2009) RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. *Cell* **138**, 576-591
23. Ablasser, A., Bauernfeind, F., Hartmann, G., Latz, E., Fitzgerald, K. A., and Hornung, V. (2009) RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. *Nature immunology* **10**, 1065-1072
24. Valentine, R., and Smith, G. L. (2010) Inhibition of the RNA polymerase III-mediated dsDNA-sensing pathway of innate immunity by vaccinia virus protein E3. *J Gen Virol* **91**, 2221-2229
25. Boguslawski, S. J., Smith, D. E., Michalak, M. A., Mickelson, K. E., Yehle, C. O., Patterson, W. L., and Carrico, R. J. (1986) Characterization of monoclonal antibody to DNA:RNA and its application to immunodetection of hybrids. *Journal of immunological methods* **89**, 123-130
26. Bolstad, B. M., Irizarry, R. A., Astrand, M., and Speed, T. P. (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. *Bioinformatics* **19**, 185-193
27. Vlachos, I. S., Kostoulas, N., Vergoulis, T., Georgakilas, G., Reczko, M., Maragkakis, M., Paraskevopoulou, M. D., Prionidis, K., Dalamagas, T., and Hatzigeorgiou, A. G. (2012) DIANA miRPath v.2.0: investigating the combinatorial effect of microRNAs in pathways. *Nucleic Acids Res* **40**, W498-504
28. Schmittgen, T. D., Jiang, J., Liu, Q., and Yang, L. (2004) A high-throughput method to monitor the expression of microRNA precursors. *Nucleic Acids Res* **32**, e43
29. Dragan, A. I., Casas-Finet, J. R., Bishop, E. S., Strouse, R. J., Schenerman, M. A., and Geddes, C. D. (2010) Characterization of PicoGreen interaction with dsDNA and the origin of its fluorescence enhancement upon binding. *Biophys J* **99**, 3010-3019
30. Haugland, R. P. (2005) *The handbook: a guide to fluorescent probes and labeling technologies*, Molecular probes
31. Frank, P., Albert, S., Cazenave, C., and Toulme, J. J. (1994) Purification and characterization of human ribonuclease HII. *Nucleic Acids Res* **22**, 5247-5254
32. Xu, B., and Clayton, D. A. (1996) RNA-DNA hybrid formation at the human mitochondrial heavy-strand origin ceases at replication start sites: an implication for RNA-DNA hybrids serving as primers. *Embo J* **15**, 3135-3143
33. Shaw, N. N., and Arya, D. P. (2008) Recognition of the unique structure of DNA:RNA hybrids. *Biochimie* **90**, 1026-1039
34. Wu, L., Pan, J., Thoroddsen, V., Wysong, D. R., Blackman, R. K., Bulawa, C. E., Gould, A. E., Ocain, T. D., Dick, L. R., Errada, P., Dorr, P. K., Parkinson, T., Wood, T., Kornitzer, D., Weissman, Z., Willis, I. M., and McGovern, K. (2003) Novel small-molecule inhibitors of RNA polymerase III. *Eukaryot Cell* **2**, 256-264
35. Wang, Z., and Roeder, R. G. (1997) Three human RNA polymerase III-specific subunits form a subcomplex with a selective function in specific transcription initiation. *Genes Dev* **11**, 1315-1326
36. Chan, Y. A., Hieter, P., and Stirling, P. C. (2014) Mechanisms of genome instability induced by RNA-processing defects. *Trends Genet*
37. Hamperl, S., and Cimprich, K. A. (2014) The contribution of co-transcriptional RNA:DNA hybrid structures to DNA damage and genome instability. *DNA Repair (Amst)*
38. Pedrali-Noy, G., and Spadari, S. (1979) Effect of aphidicolin on viral and human DNA polymerases. *Biochem Biophys Res Commun* **88**, 1194-1202

39. Wang, Y., and Taniguchi, T. (2013) MicroRNAs and DNA damage response: implications for cancer therapy. *Cell cycle* **12**, 32-42
40. Pothof, J., Verkaik, N. S., Hoeijmakers, J. H., and van Gent, D. C. (2009) MicroRNA responses and stress granule formation modulate the DNA damage response. *Cell Cycle* **8**, 3462-3468
41. Gao, M., Wei, W., Li, M. M., Wu, Y. S., Ba, Z., Jin, K. X., Liao, Y. Q., Adhikari, S., Chong, Z., Zhang, T., Guo, C. X., Tang, T. S., Zhu, B. T., Xu, X. Z., Mailand, N., Yang, Y. G., Qi, Y., and Rendtlew Danielsen, J. M. (2014) Ago2 facilitates Rad51 recruitment and DNA double-strand break repair by homologous recombination. *Cell Res* **24**, 532-541
42. Borchert, G. M., Lanier, W., and Davidson, B. L. (2006) RNA polymerase III transcribes human microRNAs. *Nat Struct Mol Biol* **13**, 1097-1101
43. Canella, D., Praz, V., Reina, J. H., Cousin, P., and Hernandez, N. (2010) Defining the RNA polymerase III transcriptome: Genome-wide localization of the RNA polymerase III transcription machinery in human cells. *Genome Res* **20**, 710-721
44. Bussing, I., Yang, J. S., Lai, E. C., and Grosshans, H. (2010) The nuclear export receptor XPO-1 supports primary miRNA processing in *C. elegans* and *Drosophila*. *Embo J* **29**, 1830-1839
45. Stade, K., Ford, C. S., Guthrie, C., and Weis, K. (1997) Exportin 1 (Crm1p) is an essential nuclear export factor. *Cell* **90**, 1041-1050
46. Hiller, B., Achleitner, M., Glage, S., Naumann, R., Behrendt, R., and Roers, A. (2012) Mammalian RNase H2 removes ribonucleotides from DNA to maintain genome integrity. *J Exp Med* **209**, 1419-1426
47. Brown, T. A., Tkachuk, A. N., and Clayton, D. A. (2008) Native R-loops persist throughout the mouse mitochondrial DNA genome. *The Journal of biological chemistry* **283**, 36743-36751
48. Nakama, M., Kawakami, K., Kajitani, T., Urano, T., and Murakami, Y. (2012) DNA-RNA hybrid formation mediates RNAi-directed heterochromatin formation. *Genes Cells* **17**, 218-233
49. Archambault, J., and Friesen, J. D. (1993) Genetics of eukaryotic RNA polymerases I, II, and III. *Microbiol Rev* **57**, 703-724
50. Goodrich, J. A., and Kugel, J. F. (2006) Non-coding-RNA regulators of RNA polymerase II transcription. *Nature reviews. Molecular cell biology* **7**, 612-616
51. Skourti-Stathaki, K., Proudfoot, N. J., and Gromak, N. (2011) Human senataxin resolves RNA/DNA hybrids formed at transcriptional pause sites to promote Xrn2-dependent termination. *Mol Cell* **42**, 794-805
52. Fukuda, T., Yamagata, K., Fujiyama, S., Matsumoto, T., Koshida, I., Yoshimura, K., Mihara, M., Naitou, M., Endoh, H., Nakamura, T., Akimoto, C., Yamamoto, Y., Katagiri, T., Foulds, C., Takezawa, S., Kitagawa, H., Takeyama, K., O'Malley, B. W., and Kato, S. (2007) DEAD-box RNA helicase subunits of the Drosha complex are required for processing of rRNA and a subset of microRNAs. *Nat Cell Biol* **9**, 604-611
53. Horton, N. C., and Finzel, B. C. (1996) The structure of an RNA/DNA hybrid: a substrate of the ribonuclease activity of HIV-1 reverse transcriptase. *J Mol Biol* **264**, 521-533
54. Takano, T., and Hatanaka, M. (1975) DNA-RNA hybrid in cells infected by murine leukemia virus. *Cold Spring Harb Symp Quant Biol* **39 Pt 2**, 1009-1014

## FOOTNOTES

\*This work was supported, in whole or in part, by a Health and Labour Sciences Research Grant 'Adjuvant database Project' of the Japanese Ministry of Health, Labour and Welfare, and a National Research Foundation grant HUI-CREATE-Cellular and Molecular Mechanisms of Inflammation to S.G.

<sup>1</sup>To whom correspondence should be addressed: Stephan Gasser (stephan\_gasser@nuhs.edu.sg) or Ken J. Ishii (kenishii@biken.osaka-u.ac.jp)

<sup>2</sup>The abbreviations used are: NKG2D, natural killer group 2, member D; POL, polymerase; rRNA, ribosomal RNA; tRNA, translational RNA; RIG-I, retinoic acid inducible gene I; BRCA1, Breast cancer susceptibility gene 1; POLR3G, polymerase (RNA) III (DNA directed) polypeptide G; DDX5, DEAD (Asp-Glu-Ala-Asp) box polypeptide 5; DDX17, DEAD (Asp-Glu-Ala-Asp) box polypeptide 17; AGO2, argonaute 2; Ara-C, cytarabine; APH, aphidicolin; KPNB1, Karyopherin (Importin) Beta 1; XPO1, exportin-1; NUP153, Nucleoporin 153kDa.

## FIGURE LEGENDS

**FIGURE 1. RNA:DNA hybrids exist in the cytosol of human lung cancer cells.** *A*, The human lung carcinoma cell line was stained with 10  $\mu$ l/ml of the vital dsDNA-specific dye PicoGreen (Green) for 1 hr and 100 nM of the mitochondria-specific vital dye MitoTracker (Red) for 30 minutes. Samples shown in lower row were pretreated with 0.5 U/ml of RNase H. *B* and *C*, 3D isosurface rendering (*B*) and quantification (*C*) of PicoGreen staining in the nucleus and cytosol of images shown in (*A*). One-tailed Wilcoxon test was performed. Error bars represent SEM, \* $P < 0.05$  (*D*) A549 cells were stained with the RNA:DNA hybrid-specific antibody S9.6 (Green) and the mitochondrial marker COX IV (Red) in the presence of Hoechst (Blue). Cells shown in the lower row were pretreated with 0.5 U/ml of RNase H before staining. *E* and *F*, 3D isosurface rendering (*E*) and quantification (*F*) of RNA:DNA hybrid staining of images shown in (*D*). *G*, 3D isosurface rendering of staining of A549 cells with PicoGreen (Green), RNA:DNA hybrid-specific antibodies (Red) and Hoechst (Blue). One-tailed Wilcoxon test was performed. Error bars represent SEM, \* $P < 0.05$ .

**FIGURE 2. Presence of cytosolic RNA:DNA hybrids in human tumor cell lines.** *A*, The human colorectal carcinoma cell lines LoVo, HCT 116, and HT29, the human acute monocytic leukemia cell line THP-1, the human cervix carcinoma cell line HeLa, and the human normal lung tissue derived cell line MRC-5, were stained for the presence of RNA:DNA hybrids (Red) and Hoechst (Blue). *B*, The colorectal adenocarcinoma cell lines LoVo, HCT116 and HT29 were stained with PicoGreen (Upper row). Bright field images (DIC) of cells are shown in the lower row. *C*, 3D isosurface rendering of confocal images A549 cells stained for the presence of dsDNA (green) and RNA:DNA hybrids (Red) in the presence of Hoechst dye (Blue). Colocalization of dsDNA and RNA:DNA hybrids (Yellow) was determined by Volocity computational image analysis.

**FIGURE 3. RNA Pol III is essential for the presence of cytosolic RNA:DNA hybrids.** *A*, A549 cells were treated with the indicated concentration of RNA Pol III inhibitor ML-60218 for 3 hrs, before staining with 10  $\mu$ l/ml PicoGreen (Green) for 1 hr and 100 nM of the mitochondria-specific vital dye MitoTracker (Red) for 30 minutes. *B*, Cytosolic and nuclear intensity quantification of images shown in (*A*). Two-tailed Wilcoxon test was performed. Error bars represent SEM, \* $P < 0.05$ . *C*, A549 cells were treated with indicated concentration of RNA Pol III inhibitor ML-60218 for 3 hrs, before staining of cells with RNA:DNA hybrid-specific S9.6 antibodies (Green) and Hoechst (Blue). *D*, Cytosolic and nuclear intensity quantification of images shown in (*C*). Two-tailed Wilcoxon test was performed. Error bars represent SEM, \* $P < 0.05$ .

**FIGURE 4. Genetic knockdown of RNA Pol III decreases cytosolic RNA:DNA hybrid levels.** *A*, A549 cells were transfected with 25 nM of siNEG (negative control siRNA), or siRNA against POLR3G

(siPOLR3G\_1, siPOLR3G\_2). 72 hrs after transfection, cells were stained for RNA:DNA hybrids (Green), POLR3G (Red), and Hoechst (Blue). *B*, Some cells in (*A*) were subjected to RNA isolation for measurement of *POLR3G* mRNA expression with respect to *HPRT1*. One-tailed Student's t-test was performed. Error bars represent SEM, \**P* < 0.05.

**FIGURE 5. Levels of cytosolic RNA:DNA hybrids are not modulated by genotoxic replication inhibitors.** *A*, A549 cells were treated with 10  $\mu$ M of the genotoxic DNA replication inhibitor Ara-C for 15 hrs, and stained RNA:DNA hybrids (Green) and POLR3G (Red) in the presence of Hoechst (Blue). *B*, A549 cells treated with Ara-C as in *A*, and stained with 10  $\mu$ l/ml PicoGreen (Green), POLR3G-specific antibody (Red), and Hoechst (Blue). *C*, A549 cells were treated with 4  $\mu$ M of aphidicolin (APH), an inhibitor of DNA polymerase for 15 hrs, and stained with RNA:DNA hybrids (Green) in the presence of Hoechst (Blue). *D*, A549 cells were treated with 10  $\mu$ M of ATM inhibitor (ATMi), or ATR inhibitor (ATRi), or both for 15 hrs. Cells were stained with RNA:DNA hybrids (Red) in the presence of Hoechst (Blue).

**FIGURE 6. Cytosolic RNA:DNA hybrids interact with microRNA machinery proteins.** *A*, Cytosolic fractions of A549 cells were subjected to immunoprecipitation using RNA:DNA hybrid-specific S9.6 antibodies. A part of the cytosolic fraction was pretreated with 0.5 U/ml RNase H. Immunoprecipitated proteins were detected by SDS-PAGE gel electrophoresis and silver staining. Indicated bands were analyzed by mass spectrometry. *B* and *C*, A549 cells were treated with DMSO or 10  $\mu$ M Ara-C for 15 hrs, and harvested for cell fractionation after fixation. Cytosolic fractions were subjected to immunoprecipitation with RNA:DNA-specific S9.6 antibodies. Immunoblot analysis of immunoprecipitated proteins probed with antibodies specific for DDX17 (*B*) and AGO2 (*C*).

**FIGURE 7. Deregulation of microRNAs by RNA Pol III inhibition.** *A*, A549 cells were treated with 10  $\mu$ M of the RNA Pol III inhibitor ML-60218 (RPIII inh.) or DMSO for 24 hrs. Some cells were further treated with Ara-C for 15 hrs. Heat map of global miRNA expression profile from total RNA extracted after treatment is shown. All expression profiles were quantile-normalized and then fold values with reference to control (DMSO) were used for plotting this heatmap. 81 probes had at least 3-fold differential expression in any pair of conditions and were pre-selected for this plot. *B*, Scatter-plot of miRNA expression profiles between control (DMSO) and ML-6028-treated samples. Decision surface was plotted for at least 3-fold change to or from control. Highly upregulated and downregulated miRNAs after RPIII inhibitor treatment were identified in the table (lower columns). *C*, A549 cells were treated with 10  $\mu$ M of the RNA Pol III inhibitor ML-60218 (RPIII inh.) or DMSO for 24 hrs. Expression levels of primary, precursor, and mature miR-4499 were examined from isolated RNA. Two-tailed Student's t-test was performed. Error bars represent SEM, \**P* < 0.05.

**FIGURE 8. RNA transport and mRNA surveillance pathways are potential targets of RNA polymerase III modulated miRNAs.** *A*, List of predicted miRNAs regulated by POL III were analyzed for potential gene targets by using online resource DIANA-miRPath. Yellow boxes indicate genes that are regulated by one miRNA in response to POL III inhibition. The red boxes indicate potential target genes regulated by more than one miRNA upon POL III inhibition. *B*, mRNA expression levels of three potential genes, each targeted by more than one miRNA. Total RNA was extracted from A549 cells after treatment with 10  $\mu$ M of the RNA Pol III inhibitor ML-60218 (RPIII inh.) or DMSO for 24 hrs, and subjected to real time PCR analysis. Normalization was done with respect to *HPRT1* housekeeping gene, and further compared against DMSO-treated cells. One-tailed Wilcoxon test was performed. Error bars represent SEM, \**P* < 0.05.

**FIGURE 9. Exportin 1 function is required for the presence of cytosolic RNA:DNA hybrids.** *A*, A549 cells were treated with the indicated concentration of Exportin 1 inhibitor, Leptomycin B (LMB) for 16 hrs, before staining with RNA:DNA hybrid-specific S9.6 antibodies (Green), COXIV (Red) and Hoechst (Blue). *B*, A549 cells were treated with increasing concentration of LMB (0, 10, 20, 30, and 40 nM) for 16 hrs,

## POL III links cytosolic RNA:DNA hybrids to miRNAs

before staining with RNA:DNA hybrid-specific S9.6 antibodies, COXIV, and Hoechst. Microscope images were quantified for cytosolic and mitochondrial intensity of cells. Two-tailed Student's t-test was performed. Error bars represent SEM, \*P < 0.05.

FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5

POL III links cytosolic RNA:DNA hybrids to miRNAs




FIGURE 6




FIGURE 7




FIGURE 8




FIGURE 9

